

Beth Israel Lahey Health 
 Beth Israel Deaconess Medical Center

Department / Committee:	IBC Committee
Institution:	BIDMC, Boston Campus
Membership Present:	Alex Toker, Chair Nanette Moss, BSO Robert Griffin, BSO Gary Schweon, Unaffiliated Community Member Peter Weller, IBC Member; Infectious Disease Deborah Barbeau, IBC Member; Employee Health Lauren Peter, IBC Member; Research Compliance Barbara Garibaldi, IBC Member; Vet Adrein Sipos, Unaffiliated Community Member Simon Dillon, IBC Member; Genomics Jack Lawler; IBC Member; Pathology
Date:	October 1, 2025
Meeting Place:	Zoom Meeting
Meeting Convened At:	1:00 PM
Meeting Type:	Closed
Quorum: Quorum was met (at least one half plus one of roster present) and no committee members left the meeting early.	

Item Category	Topic	Discussion / Follow-Up
	Call to Order	Quorum present for meeting.
Meeting Minutes Approval	September 3, 2025 Minutes	No issues or questions regarding these minutes from members. Presiding motioned to approve, motion second, minutes were approved.
Scheduled Business	<i>Barouch</i> — 25-0048 Amendment: “Analysis of Immune Responses During Measles Infection NIH Section: Not Applicable	Review/Clinical Review: The BSO presented the risk assessment. This is an amendment to a previously approved IBC protocol that requests to add research personnel as well as new human cell lines for <i>in-vitro</i> work to test the efficacy of antivirals against measles viruses. Lab has been inspected and is in good compliance. Staff training must be confirmed prior to final approval. Biosafety Level Approval: Biosafety Level-2 (BSL-2) for the addition of cell lines, which is consistent with the already assigned BSL-2 Discussion: Employee Health confirmed that all staff are up to date with measles immunity. No additional questions or concerns from committee members. Vote to Approve: For: 9 Against: 0 Abstain: 0
Scheduled Business	<i>Kirby</i> — 25-0059-R: Bacillus anthracis pathogenesis NIH Section: III-D	Review/Clinical Review: The BSO presented the risk assessment. This is a 5-year rewrite of a previously approved protocol. The lab is proposing new organisms for its work to determine virulence factors in Bacillus anthracis as well as selectable markers (resistance) and counter selectable markers (susceptibility). Of note, no clinically relevant antibiotic resistance genes are

Meeting Minutes

		<p>to be cloned in experiments. The lab has been inspected and is in good compliance. Staff training must be confirmed prior to final approval.</p> <p>Biosafety Level Approval: Biosafety Level-2 (BSL-2)</p> <p>Discussion: No additional questions or concerns from committee members.</p> <p>Vote to Approve: For: 10 Against: 0 Abstain: 0</p>
Scheduled Business	<p><i>Kahn</i> — 25-0060-R: Production and use of Lentivirus to investigate mechanisms leading to insulin resistance and obesity NIH Section: III-D</p>	<p>Review/Clinical Review: The BSO presented the risk assessment. This is a 5-year rewrite of a previously approved protocol and does not include new work. The lab uses commercially available, 3rd generation or newer lentiviruses and uses them in <i>in vitro</i> experiments to identify proteins that influence insulin resistance. The lab has been inspected and is in good compliance. Staff training must be confirmed prior to final approval. The protocol sections on risk assessment and shipping/transporting should be fully completed. The BSO will follow-up with the PI regarding this.</p> <p>Biosafety Level Approval: Biosafety Level-2 (BSL-2)</p> <p>Discussion: No additional questions or concerns from committee members.</p> <p>Vote to approve pending completion of the protocol form sections noted above: For: 10 Against: 0 Abstain: 0</p>
Scheduled Business	<p><i>Kirby</i> — 25-0042-R Amendment: Novel Therapeutics for Gram Negative Pathogens II NIH Section: III-E</p>	<p>Review/Clinical Review: The BSO presented the risk assessment. This is an amendment to a previously approved IBC protocol and requests to add the T7 bacteriophage to the registration to delete the T7 RNA polymerase gene from the T7 bacteriophage and then clone its genome into a BAC vector (bacterial artificial chromosome). No T7 phage can be produced from this clone. The lab has been inspected and is in good compliance. New staff have been added and confirmation of completing CRST (lab safety training) for final approval.</p> <p>Biosafety Level Approval: Biosafety Level-1 (BSL-1)</p> <p>Discussion: No additional questions or concerns from committee members.</p> <p>Vote to Approve: For: 10 Against: 0 Abstain: 0</p>
Scheduled Business	<p><i>Barouch</i> — 25-0055 Amendment: Propagation and Study of BSL2/BSL2+ Live Virus Isolates of Existing and Emerging Pathogens NIH Section: N/A</p>	<p>Review/Clinical Review: The BSO presented the risk assessment. This is an amendment to a previously approved IBC protocol and requests to include three additional Arena Viruses to the protocol; Amapari, Ippy and Parana viruses. Lab has been inspected and is in good compliance. Staff training must be confirmed prior to final approval.</p> <p>Biosafety Level Approval: Biosafety Level-2+ (BSL-2+)</p> <p>Discussion: No additional questions or concerns from committee members.</p> <p>Vote to Approve:</p>

Meeting Minutes

		<p>For: 10 Against: 0 Abstain: 0</p>
Scheduled Business	<p><i>Barouch</i> — 25-0021-R Amendment: "The Immunogenicity of Influenza Virus NIH Section: III-D</p>	<p>Review/Clinical Review: The BSO presented the risk assessment. This is an amendment to a previously approved IBC protocol that requests to include additional strains of influenza, which are generated at a collaborator's laboratory. Of note, all manipulations have been previously approved. The lab has been inspected and is in good compliance. Staff training must be confirmed prior to final approval.</p> <p>Biosafety Level Approval: Biosafety Level-2+ (BSL-2+) for consistency with other previously approved strains.</p> <p>Discussion: No additional questions or concerns from committee members.</p> <p>Vote to Approve: For: 10 Against: 0 Abstain: 0</p>
Scheduled Business	<p><i>Barouch</i> — 24-0025-R Amendment: Immunogenicity of Zika, other Flaviviruses, and Oropouche Virus NIH Section: N/A</p>	<p>Review/Clinical Review: The BSO presented the risk assessment. This is an amendment to a previously approved IBC protocol and requests to add Oropouche clinical isolates. No new processes or manipulations are proposed. The lab has been inspected and is in good compliance. Additional staff have been added to the protocol and confirmation of CRST (lab safety training) must be completed prior to final approval.</p> <p>Biosafety Level Approval: Biosafety Level-2 (BSL-2)</p> <p>Discussion: One member asked if the approval letter will mention a requirement for meeting with Occupational Health, and if so, would it be more appropriate to include a general warning instead. The BSO indicated that there is a general stipulation built into the approval letter that recommends staff who are considering having children, or are of childbearing age, should check in with Occupational Health first. The BSO will confirm this information and include phrasing that indicates checking in with Occupation Health is optional and not required.</p> <p>No additional questions or concerns from committee members.</p> <p>Vote to Approve: For: 10 Against: 0 Abstain: 0</p>
Scheduled Business	<p><i>Weiskopf</i> — 25-0066: Immuno-engineering of novel therapies for cancer and other diseases NIH Section: III-D, III-E</p>	<p>Review/Clinical Review: The BSO presented the risk assessment. This new lab studies the interactions between the immune system and cancer with two main overall goals; identify new receptors and signaling pathways that control the ability of immune cells to attack cancer cells and use this information to create and test new drugs that provoke immune cells to attack and eliminate cancer cells. The lab performs a number of experimental approaches that may be applied to neurodegenerative studies, in addition to cancer, as well. The lab is new and will be inspected when fully set up. Lab staff will be expected to take CRST and lab specific training and will be confirmed at time of inspection.</p> <p>Biosafety Level Approval: Biosafety Level-2 (BSL-2)</p> <p>Animal Biosafety Level Approval: Animal Biosafety Level-2 (BSL-2) for human cells going into animals</p> <p>Discussion:</p>

Meeting Minutes

		<p>BSO noted when the lab is inspected they will confirm if BSL-2+ is required. One member noted that the protocol is being reviewed during the IACUC meeting tomorrow. One member asked for clarification on staff handling of the antibody drug conjugates that are being produced by this lab. BSO indicated that when his lab is inspected, they will confirm that his facilities and disposal sources are available for the hazardous materials. Another member noted that duplicate information is listed on page 3-4 under Recombinant DNA.</p> <p>No additional questions or concerns from committee members.</p> <p>Vote to Approve: For: 9 Against: 0 Abstain: 0</p>
Open Discussion	Other	<p>One member asked if the approval letters have a general statement reminding staff they can meet with Employee Health with any questions or concerns, they might have regarding personal safety, additional needs they might have, etc. BSO indicated there is not a general statement presently, only a statement for when particular groups of individuals are concerned. The Committee agreed that a general statement about this should be included in approval letters and the BSO will work on drafting this statement.</p> <p>Another member indicated that some PIs at another institution are receiving notifications from the National Institutes of Health (NIH) asking them to confirm that they are not conducting dangerous gain-of-function research and they are requiring that a response be completed within 5 days. Committee members were asked to inform the BSO if anyone receives this request so they can assist with a response.</p>
Scheduled Business	Shipping Training Presentation	Shipping compliance training overview was given to committee members related to US Department of Transportation and the International Air Transport Association. This covered who needs training, the content of the training materials, the required training frequency, and how BIDMC staff can access these trainings.
Reported Incidents		No incidents to report
Adjournment		Meeting adjourned at 1:30 PM.
General	Next meeting	The next meeting will be held on November 5 at 1:00 PM on Zoom Meeting